Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07138040

Re-Engaging AYA Survivors in Cancer-Related Healthcare

The goal of this clinical trial is to test the efficacy (how well they work) of different digital interventions that deliver information to adolescent and young adult (AYA) survivors of childhood cancer to promote re-engagement in cancer-related long-term follow-up care (LTFU). The main aims are:

* To test the efficacy of adaptive interventions (AIs) that begin with low touch intervention (LTI) as compared to written information (WI) on attending an appointment, and self-reported self-management among AYA. * To identify the most efficacious second-stage strategy for those who initially schedule/attend an appointment (maintenance vs. step-up) and for those who do not (step-up vs. step-up maximum). * To assess multilevel factors contributing to the effects of re-engaging AYA and how best to integrate AIs into practice.

Throughout the duration of the study, participants will complete four surveys, receive a series of interventions, and may be asked to participate in an interview (post-intervention).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

15 year–29 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Nationwide Children's Hospital, Columbus, Ohio, United States

Loading trial locations.

About this study

Over 80% of children diagnosed with cancer become long-term survivors; however, 70% develop chronic or life-threatening late effects from treatment, and these often emerge during young adulthood. Guidelines recommend annual long-term follow-up care (LTFU) to manage and monitor for late effects, recurrence, or new cancer(s). Yet, as risk for late effects increases in young adulthood and survivors transition into adult-focused care, engagement in care plummets. Disengagement from LTFU leaves adolescent and young adult survivors (AYA) vulnerable to delayed or poorly managed diagnoses and relates to lower knowledge and self-management abilities. Thus, interventions targeting re-engagement of AYA are critical for this vulnerable population. The REACH (Re-Engaging AYA survivors in Cancer-related Healthcare) study will test a low touch intervention (LTI), consisting of reminder "nudge" text messages and informational resources for up to 4 weeks compared to an enhanced usual care group that will receive written information (WI) only.

In Stage 2, AYA will be re-randomized based on responsiveness to Stage 1 (i.e., whether or not they made an appointment) into 16 weeks of intervention. Responders will either be re-randomized to receive a continued intervention (maintenance) or a stepped-up condition, while non-responders will only receive a stepped-up condition. Step-up may include expanded LTI (more text messages) or a high touch intervention (HTI). The HTI includes text messages and digital resources, including a personalized survivorship care plan (SCP), and a mobile-friendly platform with information tailored to variables such as barriers to care, treatment history and recommendations, and a personal health goal. Additionally, social worker and/or nurse support will be available to help overcome barriers (e.g., access care).

The intervention options in Stage 2 are intended to enhance self-management beyond simply attending LTFU in order to sustain long-term engagement. Outcomes are measured after Stage 1 (T2), Stage 2 (T3) and at 36 weeks (T4).

It is expected that those who start with LTI versus WI will be more likely to attend a LTFU appointment by T4. For Stage 2, those who receive the stepped-up condition compared to those with maintenance, and those who received HTI compared to LTI, will be more likely to attend an appointment by T4. Attending an appointment by T3 and indices of self-management are secondary outcomes. The study team will assess moderators of intervention outcomes, intervention engagement, acceptability, feasibility, and cost. Qualitative interviews will assess multilevel barriers and facilitators of future implementation with stakeholders (AYA, parents/supports, providers, administrators). This trial aims to promote optimal engagement in LTFU and self-management for AYA survivors, improving outcomes and reducing disparities. For Stage 2, those who receive the stepped-up condition compared to those with maintenance, and those who received HTI compared to LTI, will be more likely to attend an appointment by T4.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for AYA

  • 15-29 years old
  • History of a childhood cancer diagnosis, diagnosed prior to age 22
  • Has not had a cancer-related follow-up visit in at least 15 months (or is 3 months past recommended follow-up)
  • U.S. resident (not international patient)
  • Has previously attended a cancer-related appointment at Children's Hospital of Philadelphia, or Nationwide Children's Hospital or Penn
  • At least 2 years from end of treatment and 5 years from diagnosis
  • English proficient
  • For AYA under age 18, must have a caregiver to provide informed consent

Exclusion criteria

for AYA

  • Cognitive impairment limiting participation
  • Received surgery only treatment
  • Transferred to primary care
  • Currently living with cancer diagnosis (either new, metastatic, recurrence, or relapse)
  • Absence of documentation of treatment history
  • Absence of inclusion criteria above

Inclusion criteria

for Support Person of AYA

  • Primary caregiver or other support person (e.g. partner, sibling, other caregiver)
  • At least 18 years old
  • U.S. resident
  • English proficient

Exclusion criteria

for Support Person of AYA

  • No involvement in the AYA's healthcare
  • AYA Decline support person's participation
  • Absence of inclusion criteria above

Treatment and study plan

Stage 1 Written Information

Behavioral

Stage 1 WI: consists of a letter from the survivorship care team with information about long-term follow-up care and relevant contacts to schedule an appointment.

Other names: S1 WI

Stage 1 Low Touch Intervention

Behavioral

Stage 1 LTI: consists of the WI stage 1 letter, a copy of their treatment summary with instructions for creating their own survivorship care plan, and one text message per week with information to schedule a follow-up care appointment.

Other names: S1 LTI

Stage 2 Written Information

Behavioral

Stage 2 WI: consists of a letter from the survivorship care team with information about what to expect at a long-term follow-up care appointment.

Other names: S2 WI

Stage 2 Low Touch Intervention

Behavioral

Stage 2 LTI: consists of the WI stage 2 letter, a copy of their treatment summary with instructions for creating their own survivorship care plan, and two to three non-tailored (generic) text messages per week related to scheduling an appointment, overcoming barriers to follow-up care, and health self-management.

Other names: S2 LTI

Stage 2 High Touch Intervention

Behavioral

Stage 2 HTI: consists of personalized mobile-friendly dashboard containing the WI letters, their treatment summary, survivorship care plan, and a growing discover section with helpful tailored resources. They will also receive four to six text messages per week with personalized messages related to their chosen health goal, personal barriers to attending cancer-related follow-up care, treatment-related risks, information about scheduling their long-term follow-up appointments, health self-management, and fun texts consisting of celebrity quotes, memes, and altruistic messages.

Other names: S2 HTI, HTI

Primary outcomes

  1. Re-Engagement in Care - by T4

    Time frame: 36 weeks (T4)

    Percentage of participants who re-engage in care (attend a LTFU appointment) by T4 as measured by electronic health record (EHR) review. If attendance is not viewable in EHR, it will be ascertained by self-report (yes/no).

Secondary outcomes

  1. Re-Engagement in Care - by T3

    Time frame: 20 weeks (T3)

    Percentage of participants who re-engage in care (attend a LTFU appointment) by T3 as measured by electronic health record (EHR) review. If attendance is not viewable in EHR, it will be ascertained by self-report (yes/no).

  2. AYA Self-Management (Health Knowledge Inventory)

    Time frame: 2 times - at 20 weeks (T3) and 36 weeks (T4)

    Measured via self-reported participant questionnaire. For the Health Knowledge inventory (28 items), a total percentage correct score will be reported 0-100%, with higher scores representing greater self-management.

  3. AYA Self-Management (Transition Readiness Questionnaire)

    Time frame: 2 times - at 20 weeks (T3) and 36 weeks (T4)

    Measured via self-reported participant questionnaire. For the Transition Readiness Assessment Questionnaire (20 items), a total average score will be reported ranging from 1-5, with higher scores representing greater self-management.

  4. AYA Self-Management (Self-Management Skills)

    Time frame: 2 times - at 20 weeks (T3) and 36 weeks (T4)

    Measured via self-reported participant questionnaire. For the Self-management Skills Scale (15 items), a total percentage score will be reported ranging from 0-100%, with higher scores representing greater self-management.

  5. AYA Self-Management (Health Goal Progress)

    Time frame: 2 times - at 20 weeks (T3) and 36 weeks (T4)

    Measured via self-reported participant questionnaire. For the Health Goal Progress (5 items), a total score will be reported ranging from 5-24, with higher scores representing greater self-management.

  6. AYA Self-Management (Allocation of Treatment Responsibility)

    Time frame: 2 times - at 20 weeks (T3) and 36 weeks (T4)

    Measured via self-reported participant questionnaire. For the Allocation of treatment responsibility, clinic appointment subscale (5 items), a total score will be reported ranging from 5-20, with higher scores representing greater self-management.

  7. AYA Self-Management (Transition Readiness Inventory)

    Time frame: 2 times - at 20 weeks (T3) and 36 weeks (T4)

    Measured via self-reported participant questionnaire. For the Transition Readiness Inventory (28 items), a total average score will be reported ranging from 1-5, with higher scores representing greater self-management.

Study contacts

Contact information is provided by the study sponsor or research team.

Lisa Schwartz, PhD

CONTACT

[email protected]

(267) 426-0355

Sara King-Dowling, PhD

CONTACT

[email protected]

(267) 426-5562

Sponsors and collaborators

Lead sponsor

Children's Hospital of Philadelphia

Other

Collaborators

  • National Cancer Institute (NCI)
  • Nationwide Children's Hospital
  • University of Pennsylvania

Registry information

Official study title

Re-Engaging AYA Survivors in Cancer-Related Healthcare: A Sequential Multiple Assignment Randomized Trial

Acronym: REACH:SMART

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Aug 22, 2025
Registry last updated
Feb 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.